Skip to main content
Bora logo

Bora — Investor Relations & Filings

Ticker · 6472 ISIN · TW0006472004 LEI · 254900MK7O5C2UX1SY03 TW Manufacturing
Open in API
Filings indexed 65 across all filing types
Latest filing 2026-05-26 Share Issue/Capital Cha…
Country TW Taiwan
Listing TW 6472

About Bora

https://bora-corp.com/

Bora Pharmaceuticals Co., Ltd. is a global pharmaceutical service provider that operates through a "dual-engine" business model, integrating comprehensive Contract Development and Manufacturing Organization (CDMO) services with the development and commercialization of specialty pharmaceuticals. The company provides end-to-end solutions ranging from formulation development and clinical trial materials to large-scale commercial manufacturing. Its technical capabilities encompass a diverse array of dosage forms, including oral solids, liquids, and semi-solids. With a manufacturing footprint spanning multiple continents, the company serves global markets by leveraging advanced production technologies and rigorous quality management systems. Bora Pharmaceuticals focuses on strategic growth through acquisitions and partnerships, aiming to enhance manufacturing efficiency and accelerate the delivery of complex therapeutic treatments to patients worldwide.

Recent filings

Filing Released Lang Actions
115年5月變更登記
Share Issue/Capital Change Classification · 85% confidence The document is a public disclosure from a listed company’s information observatory detailing the company’s share capital structure: par value, authorized shares, issued shares, paid-in capital, sources of capital increases (e.g., warrant conversion) and cancellations. This is a specific announcement of share capital changes rather than an earnings release, management discussion, or certificate. It fits the definition of a Share Issue/Capital Change filing (SHA).
2026-05-26 Chinese
115年05月僑外投資持股
Regulatory Filings Classification · 80% confidence The document is a Taiwanese regulatory compliance form published on the Public Information Observation Station showing statistics of overseas and Mainland China investors’ shareholdings as of specific dates. It does not announce dividends, AGM materials, board changes, or actual financial results, nor is it a shareholder threshold crossing notification under 5%. It is a miscellaneous regulatory disclosure, so it falls under the Regulatory Filings fallback category.
2026-05-25 Chinese
115年5月變更登記
Share Issue/Capital Change Classification · 75% confidence The document is an official release from the public information observatory detailing the company’s share capital structure: par value, authorized and paid‐in capital, and the sources of capital (founding capital, capital increases, conversions, cancellations, etc.). This directly corresponds to a capital change announcement regarding share issues and adjustments, matching the Share Issue/Capital Change (SHA) category.
2026-05-23 Chinese
115年3月變更登記
Share Issue/Capital Change Classification · 85% confidence The document is an announcement of the company’s share capital structure and sources of capital changes (par value, authorized and paid‐in capital, capital increases, convertible warrants, etc.). It does not present full financial statements or an earnings or annual report but rather discloses share issue/capital change information. Therefore it fits the Share Issue/Capital Change category (Code: SHA).
2026-05-23 Chinese
公司基本資料
Regulatory Filings Classification · 88% confidence The document is a company profile disclosure from Taiwan’s public information observatory, listing basic corporate details (ticker, address, management, capital, listing dates, reporting type). It contains no financial statements, no announcements of meetings or dividends, and no event-specific content. This is a general regulatory filing that does not fit any specific report category, so it falls under RNS (Regulatory Filings).
2026-05-23 Chinese
114年年報及股東會資料 — 2025_6472_20260609FE4.pdf
Annual Report Classification · 95% confidence The document is the full 2025 Annual Report for Bora Pharmaceuticals, comprising a detailed table of contents, letter to shareholders, comprehensive financial review, corporate governance, and full financial statements. It is not merely an announcement or summary but the complete annual report. Therefore, it should be classified as an Annual Report (10-K). FY 2025
2026-05-21 English

Browse filings by year

1 year

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.